ENTITY

Oryzon Genomics (ORY SM)

54
Analysis
Health CareSpain
Oryzon Genomics, SA is a clinical stage biopharmaceutical company that develops epigenetics-based therapeutics.
more
Refresh
bullishOryzon Genomics
15 Jun 2020 16:50Issuer-paid

Oryzon Genomics - Third positive update from Phase II ALICE trial

Last Friday, Oryzon presented an updated set of data from the Phase IIa ALICE trial in acute myeloid leukaemia (AML) at the virtual 25th Congress...

Share
bullishOryzon Genomics
14 Apr 2020 18:14Issuer-paid

Oryzon Genomics - More data support vafidemstat for aggression

On 3 April 2020, Oryzon reported interim data for the first time from its two Phase IIa trials REIMAGINE-AD and ETHERAL. Both explore the company’s...

Share
bullishOryzon Genomics
20 Jan 2020 17:24Issuer-paid

Oryzon Genomics - More to come after a year of data readouts

As we expected, 2019 was a year of data readouts for epigenetics specialist Oryzon. The company presented new data from the ongoing Phase IIa...

Share
bullishOryzon Genomics
10 Dec 2019 18:32Issuer-paid

Oryzon Genomics - Maturing ALICE trial dataset continues to impress

On 9 December 2019, Oryzon presented more data from the Phase II ALICE trial at the 61st ASH annual meeting in Orlando, Florida. The single-arm,...

Share
bullishOryzon Genomics
30 Sep 2019 21:58Issuer-paid

Oryzon Genomics - Interim Phase II CLEPSIDRA results at ESMO

On 28 September 2019, Oryzon presented additional data from its Phase IIa CLEPSIDRA trial with iadademstat, a selective LSD1 inhibitor, at the ESMO...

Share
x